AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00454818 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)
Description: MYDICAR administered by antegrade epicardial coronary artery infusion
Study NCT00454818 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Saline; epicardial coronary artery infusion
Study NCT00454818 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
Description: MYDICAR administered by antegrade epicardial coronary artery infusion
Study NCT00403650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day
Study NCT04495816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acid Supplement
Description: Participants randomized to this arm will be instructed to take two of the softgels they received per day for 6 weeks. They will receive softgels containing 1,000 mg of omega-3 fatty acid. 1000 mg of omega-3 fatty acid blend including 683 mg Eicosapentaenoic Acid and 252 mg Docosahexaenoic Acid
Study NCT04495816 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo/Control
Description: Patients randomized to this arm will also be instructed to take two of the softgels they received per day for 6 weeks. They will receive placebo softgels that are indistinguishable from those containing fish oil.
Study NCT00215527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: laronidase
Description: 0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per month for four injections.
Study NCT03506568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Devers Drop Device (D3) app
Description: A universal eye drop cap monitor that accurately measures and improves eye drop-taking behavior.
Study NCT01382225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Ophthalmic Solution, 0.18%
Study NCT01382225 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as run-in and placebo comparator
Study NCT01702675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH15 50 mg
Description: ACH15 50mg capsule
Study NCT01702675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH15 250 mg
Description: ACH15 250mg capsule
Study NCT01702675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH15 500mg
Description: ACH15 500 mg capsule
Study NCT01702675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH15 - 1000mg
Description: ACH15 500mg capsule - two 500mg capsules in single dose
Study NCT01702675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH15 - 2000mg
Description: ACH15 500mg capsule (four 500mg capsules in one dose)
Study NCT01702675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH15 - 500mg
Description: ACH15 - 500mg twice a day for 7 days
Study NCT01702675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 250 mg
Description: Capsule manufactured to mimic ACH15 250 mg capsule
Study NCT01702675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 500mg
Description: Capsule manufactured to mimic ACH15 500 mg capsule
Study NCT01702675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1000mg
Description: Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)
Study NCT01702675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2000mg
Description: Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)
Study NCT01702675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 500mg
Description: Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)
Study NCT04481191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq (V260)
Description: Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution
Study NCT04481191 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq (V260)
Description: Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution
Study NCT04481191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: 0.5 mL dose IPV (Sabin strain based), administered via IM injection
Study NCT04481191 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: 0.5 mL dose IPV (Sabin strain based), administered via IM injection
Study NCT01461720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.
Study NCT01461720 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard medical care
Description: Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.
Study NCT01461720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem cells
Description: Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.
Study NCT01702194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211 IV [C14]
Study NCT01702194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211 PO [C14]
Study NCT01021475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visceral Manipulation
Description: Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks and 4 VM visits with weekly frequency with first VM visit at day 1 of drug therapy.
Study NCT01021475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPIs and/or Domperidone
Description: Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks
Study NCT03111199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherpy
Description: Cryotherapy will be used by means of ice packs over a painful region. The ice will be crushed inside a bag so that it is in an ideal size that provides a coupling in a painful column in the lumbar spine; Once it has been inserted in the plastic bag and before closing it all the air must be removed to avoid a faster thawing of the ice and have difficulties of coupling.
Study NCT03111199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS Burst
Description: The TENS Burst therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be at the maximum amplitude To generate visible muscle contraction without generating pain / discomfort. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
Study NCT03111199 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TENS Burst Placebo
Description: The TENS Burst placebo therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be on but without Produce the effects of visible muscle contractions because the channel will not be properly coupled in the apparatus so that the stimulation does not reach the patient. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
Study NCT03111199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS Burst Placebo
Description: The TENS Burst placebo therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be on but without Produce the effects of visible muscle contractions because the channel will not be properly coupled in the apparatus so that the stimulation does not reach the patient. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
Study NCT03111199 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: After the electrophysical intervention, a moment of education and awareness will be held, in which the participants will receive information about the purpose of the treatment; Anatomy and biomechanics of the lumbar spine; Chronic non-specific back pain; Cognitive, emotional, genetic, social, and lifestyle factors; Intrinsic and extrinsic physical factors, biopsychosocial model: beliefs of pain and hypervigilance; Concepts of joint protection; Energy conservation and general guidelines.
Study NCT03111199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: After the electrophysical intervention, a moment of education and awareness will be held, in which the participants will receive information about the purpose of the treatment; Anatomy and biomechanics of the lumbar spine; Chronic non-specific back pain; Cognitive, emotional, genetic, social, and lifestyle factors; Intrinsic and extrinsic physical factors, biopsychosocial model: beliefs of pain and hypervigilance; Concepts of joint protection; Energy conservation and general guidelines.
Study NCT01045083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Oral single dose
Study NCT01045083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: Oral single dose
Study NCT01045083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: Oral single dose
Study NCT01045083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral single dose
Study NCT00990665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-D and LV lead (Quartet™ lead and Promote Q® device system)
Description: Promote Q CRT-D and Quartet LV lead
Study NCT00526903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elimination Diet
Description: Daily diet change for 8 days.
Study NCT00526903 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Elimination Diet
Description: Daily diet change for 8 days.
Study NCT03376347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FlotracIQ with HPI algorithm
Description: FlotracIQ with hypotension probability indicator (HPI) algorithm connected to arterial line. The treating anesthetist is provided with guidance by means of a flowchart suggesting when to treat and what. Timing of treatment and choice of treatment is then left to the discretion of the attending physician.
Study NCT00756392 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3T MR Spectroscopy
Description: A Magnetic Resonance Spectroscopy (MRS)study of a patient's prostate will be conducted with the 3 Tesla Philips Intera Nuclear Magnetic Resonance (NMR) scanner before and after filling the rectum with barium. Scan duration from Preparation to Completion will be approximately 30 minutes. The spectra will be acquired without and with the presence of Barium solution to compare to see if the latter is advantageous.
Study NCT00813670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-001
Description: Single oral dose, or 6 days of repeated oral doses.
Study NCT04505384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left bundle branch pacing
Description: left bundle branch pacing
Study NCT04505384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biventricular pacing
Description: biventricular pacing
Study NCT00256321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 70mg/m2 IV on Days 1 and 8
Study NCT00256321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m2 PO BID from Days 1 through 14.
Study NCT00256321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 400mg PO BID from Days 1 through 21.
Study NCT03149120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
Study NCT03149120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib given at a dose of 800 mg by mouth daily.
Study NCT01600274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest-Ethinyl Estradiol (test product)
Description: One tablet of Test
Study NCT01600274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest-Ethinyl Estradiol (reference product)
Description: One tablet of Reference
Study NCT02407054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally
Study NCT02407054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Administered orally
Study NCT02407054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Administered orally
Study NCT02407054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01482962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib enteric coated tablets
Study NCT01482962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pralatrexate
Description: Pralatrexate IV infusion
Study NCT01482962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine IV infusion
Study NCT01482962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romidepsin
Description: Romidepsin IV infusion
Study NCT01942317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balneotherapy
Study NCT01498224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReSure Sealant
Description: Comparison of ReSure Sealant to suture(s)
Study NCT01498224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sutures
Study NCT01718834 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: prophylactic peptide vaccine
Description: synthetic peptide vaccine derived from HCV E1 and HCV E2 will be used for immunization of healthy volunteers
Study NCT01718834 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic peptide vaccine
Description: therapeutic peptide vaccine will immunize to HCV chronic HCV patients non responders to INF
Study NCT02455609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal drug administration
Description: pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.
Study NCT02455609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Study NCT02455609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Study NCT02455609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT01907061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: drug will be administered via IV,NG
Study NCT01907061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo or NAC will be given
Study NCT00373009 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Traditional Army training
Description: As usual training for Soldiers
Study NCT00373009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Core stabilization exercise only
Description: Core stabilization exercise
Study NCT00373009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial education class only
Description: Psychosocial education class
Study NCT00373009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core stabilization and psychosocial education
Description: Includes both core stabilization training and psychosocial education class
Study NCT02326298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use
Study NCT02326298 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use
Study NCT01797081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (24 U)
Description: 24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
Study NCT01797081 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: botulinum toxin Type A (24 U)
Description: 24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
Study NCT01797081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (12 U)
Description: 12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
Study NCT01797081 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: botulinum toxin Type A (12 U)
Description: 12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
Study NCT01797081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline
Description: Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.
Study NCT00737893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.
Study NCT00737893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Description: Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.
Study NCT04253782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Team Intervention
Description: The Team will meet with participants (remotely/electronically and/or by phone) and will ask that they select one of three options that may help with opioid addiction:~1. treatment with buprenorphine/naloxone (BUP),~2. inpatient, 12-step, or methadone regimens, or~3. education only (materials provided by the CT Community for Addiction Recovery (CCAR)).~Throughout the study, participants may switch to any other option.
Study NCT05028413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participants Shown their Breath Alcohol Content Measurement
Description: Each time a Breath Alcohol Content (BrAC) Measurement is taken by the research team, the participant is shown the measurement before completing the paper visual analog scale scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
Study NCT03634436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous
Study NCT03634436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous
Study NCT01981343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A-F Betafood
Study NCT01981343 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02829827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiprodil
Description: Radiprodil at individualized doses.
Study NCT00270231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg.
Study NCT00270231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule.
Study NCT01203826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asfotase Alfa